



# High-flow nasal oxygen versus conventional oxygen therapy in patients with COVID-19 pneumonia and mild hypoxaemia

A randomised controlled trial



### Escalation of Respiratory Support

absolute risk difference -8.2% (95% CI -18% to +1.4%); RR 0.79 (95% CI 0.59 to 1.05)



The use of HFNO did not significantly reduce the likelihood of escalation of respiratory support in patients with COVID-19 pneumonia and mild hypoxaemia. However the study is underpowered and clinically meaningful benefit from HFNO in this patient population could not be definitely ruled out.